ClinicalTrials.gg
CompletedNCT04041011Updated Jun 21, 2022

A Study of SHR-1316 and Fluzoparib(SHR-3162) in Small Cell Lung Cancer Patients

A Phase 1 interventional study of 1.Experimental: A (Part 1): Fluzoparib and SHR -1316 and 2.Experimental: B (Part 1): Fluzoparib and SHR -1316 in Small Cell Lung Cancer, sponsored by Jiangsu HengRui Medicine Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2022-06-21.

Sponsored by Jiangsu HengRui Medicine Co., Ltd. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
23
Allocation
Non-randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 365 studies in Small Cell Lung Carcinoma with a site in China — 183 open to participants now, 215 under way, 36 of them phase 3. Small Cell Lung Carcinoma · China.

Enrollment
303rd of 333
23 · median 63
Started
2019
with 25 others
Phase 1
43 of 365
24 open now
Registered
72nd of 365
by date

Among the 365 studies in Small Cell Lung Carcinoma with a site in China, this one is the 303rd largest by enrollment of the 333 interventional ones that give a count, is one of 26 that started in 2019, is one of 43 in phase 1, and was the 72nd registered.

Small Cell Lung Carcinoma

1,301 studies on the registry are indexed under Small Cell Lung Carcinoma; 365 are open to participants now.

Browse Small Cell Lung Carcinoma studies →

Open to participants now

183 of the 365 studies in Small Cell Lung Carcinoma with a site in China are open now. Recruiting first, the newest first:

178 more — sign in →

All 183 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 265 Small Cell Lung Carcinoma studies recruiting now, 175 (66%) set no upper age limit and 66 (25%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 365 studies in Small Cell Lung Carcinoma with a site in China, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety and efficacy of SHR-1316 in combination with Fluzoparib(SHR-3162) in Small Cell Lung Cancer Patients

03

Conditions studied

  • Small Cell Lung Cancer
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients must be at least 18 years of age.
  • or cytologically confirmed SCLC.
  • Failed at least one prior line of platinum-based chemotherapy.
  • Patients must have as defined by v1.1.
  • 0-1.
  • Adequate hematologic and organ function
  • Signed inform consent form

Exclusion criteria

Exclusion Criteria:

  • Active or untreated central nervous system (CNS)
  • Spinal cord compression not definitively treated with surgery and/or radiation .
  • Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures
  • other than SCLC within 5 years prior to randomization
  • History of disease
  • Positive test result for (HIV)
  • Active or
  • Severe infections
  • Subjects with a condition requiring systemic treatment with either (>10 mg daily prednisone equivalent) or other medications within 14 days of first administration of study treatment.
  • Significant cardiovascular disease
  • Prior bone marrow transplantation or solid organ transplant
  • Treatment with systemic immunosuppressive medications prior to randomization
  • Pregnant or lactating women
  • History or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the subject's participation for the full duration of the study, or is not in the best interest of the subject to participate, in the opinion of the treating investigator.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
23 participants (actual)

Study arms

  • Experimental
    1.Experimental: A (Part 1): Fluzoparib and SHR -1316

    Drug: 1.Experimental: A (Part 1): Fluzoparib and SHR -1316

  • Experimental
    2.Experimental: B (Part 1): Fluzoparib and SHR -1316

    Drug: 2.Experimental: B (Part 1): Fluzoparib and SHR -1316

  • Experimental
    3.Experimental: C (Part 2): Fluzoparib and SHR -1316 Expansion

    Drug: 3.Experimental: C (Part 2): Fluzoparib and SHR -1316 Expansion

Interventions

  • Drug1.Experimental: A (Part 1): Fluzoparib and SHR -1316

    1.Drug: Fluzoparib capsule will be given orally. Drug: SHR-1316 given intravenously (IV).

  • Drug2.Experimental: B (Part 1): Fluzoparib and SHR -1316

    2.Drug: Fluzoparib capsule will be given orally. Drug: SHR-1316 given intravenously (IV).

  • Drug3.Experimental: C (Part 2): Fluzoparib and SHR -1316 Expansion

    3.Drug: Fluzoparib capsule will be given orally. Drug: SHR-1316 given intravenously (IV).

06

What researchers measure

Primary outcomes

  1. Part 1: 1.Number of Participants with AEs and SAEs

    Time frame: Up to approximately 24 months.

  2. Part 1: 2. RP2D: Recommended dose for phase II study

    Time frame: Up to approximately 24 months.

  3. Part 2: 1. ORR: Percentage of Participants With a CR or PR

    Time frame: Up to approximately 24 months.

Secondary outcomes

  1. Part 1: 1. ORR: Percentage of Participants With a CR or PR

    Time frame: Up to approximately 24 months.

  2. Part 2: 1.Number of Participants with AEs and SAEs

    Time frame: Up to approximately 24 months.

  3. Part 2: 2.DoR: Percentage of Participants With a CR or PR

    Time frame: Up to approximately 24 months.

  4. Part 2: 3. DCR: Percentage of participants in the analysis population who have a CR, PR or SD per RECIST 1.1.

    Time frame: Up to approximately 24 months.

  5. Part 2: 4. PFS: PFS is defined as the time from randomization to the first documented disease progression per RECIST 1.1 based on blinded independent central review or death due to any cause, whichever occurs first.

    Time frame: Up to approximately 24 months.

  6. Part 2: 5. OS: Baseline until death from any cause

    Time frame: Up to approximately 24 months.

07

Study locations

1 site
  • Cancer Hospital of the University of Chinese Academy of Sciences Zhejiang Cancer Hospital
    Hangzhou, Zhejiang 310005, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2019 to primary completion in Apr 2021, 19 months.

Of 111 industry-sponsored phase 1 interventional studies under Small Cell Lung Carcinoma, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 63. This study's 19 months is below that.

Counting every sponsor, half of 143 studies reached it within 46 months; a quarter within 29 and three quarters within 64.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 31, 2019
First posted
Aug 1, 2019
StartActual
Sep 17, 2019
Primary completionActual
Apr 23, 2021
CompletionActual
Apr 23, 2021
Last update
Jun 21, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 21, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04041011
Responsible party
Sponsor
First posted
Aug 1, 2019
Start date
Sep 17, 2019
Primary completion
Apr 23, 2021
Completion
Apr 23, 2021
Last update
Jun 21, 2022

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion